CIBC Private Wealth Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$14.5M Sell
268,354
-10,873
-4% -$523K 0.02% 311
2025
Q3
$12.6M Sell
279,227
-5,525
-2% -$258K 0.02% 320
2025
Q2
$13.2M Sell
284,752
-12,332
-4% -$605K 0.02% 320
2025
Q1
$15.8M Sell
297,084
-10,498
-3% -$612K 0.03% 278
2024
Q4
$17.5M Buy
307,582
+11,057
+4% +$618K 0.03% 287
2024
Q3
$15.3M Buy
296,525
+97,758
+49% +$4.59M 0.03% 301
2024
Q2
$7.95M Sell
198,767
-13,073
-6% -$585K 0.01% 348
2024
Q1
$11.2M Buy
211,840
+5,435
+3% +$277K 0.02% 314
2023
Q4
$10.6M Sell
206,405
-8,052
-4% -$423K 0.02% 309
2023
Q3
$12.4M Sell
214,457
-76,350
-26% -$4.68M 0.03% 297
2023
Q2
$18.6M Sell
290,807
-39,898
-12% -$2.68M 0.04% 273
2023
Q1
$22.9M Sell
330,705
-14,284
-4% -$1.01M 0.05% 231
2022
Q4
$18.8M Sell
344,989
-74,525
-18% -$5.62M 0.06% 194
2022
Q3
$29.8M Sell
419,514
-10,127
-2% -$735K 0.08% 179
2022
Q2
$33.1M Sell
429,641
-12,743
-3% -$971K 0.09% 175
2022
Q1
$32.3M Buy
442,384
+9,042
+2% +$607K 0.07% 193
2021
Q4
$27M Buy
433,342
+12,270
+3% +$720K 0.06% 224
2021
Q3
$24.9M Sell
421,072
-23,978
-5% -$1.58M 0.06% 217
2021
Q2
$29.7M Sell
445,050
-28,981
-6% -$1.89M 0.07% 201
2021
Q1
$29.9M Sell
474,031
-7,466
-2% -$465K 0.08% 190
2020
Q4
$29.9M Buy
481,497
+62,415
+15% +$3.84M 0.08% 183
2020
Q3
$25.2M Buy
419,082
+114,471
+38% +$6.89M 0.08% 176
2020
Q2
$17.9M Sell
304,611
-21,738
-7% -$1.3M 0.09% 154
2020
Q1
$18.2M Buy
326,349
+7,816
+2% +$478K 0.08% 179
2019
Q4
$20.4M Buy
318,533
+104,109
+49% +$5.96M 0.07% 202
2019
Q3
$10.9M Sell
214,424
-20,832
-9% -$979K 0.04% 267
2019
Q2
$10.7M Sell
235,256
-15,861
-6% -$739K 0.04% 274
2019
Q1
$12M Sell
251,117
-60,796
-19% -$3.03M 0.05% 260
2018
Q4
$16.2M Sell
311,913
-38,161
-11% -$2.05M 0.07% 208
2018
Q3
$21.7M Sell
350,074
-12,943
-4% -$768K 0.08% 202
2018
Q2
$20.1M Sell
363,017
-18,037
-5% -$974K 0.08% 205
2018
Q1
$24.1M Sell
381,054
-23,045
-6% -$1.48M 0.1% 186
2017
Q4
$24.8M Sell
404,099
-8,561
-2% -$535K 0.11% 182
2017
Q3
$26.3M Buy
412,660
+103,357
+33% +$6.03M 0.12% 167
2017
Q2
$17.2M Sell
309,303
-27,915
-8% -$1.52M 0.11% 152
2017
Q1
$18.3M Sell
337,218
-52,305
-13% -$2.87M 0.12% 141
2016
Q4
$22.8M Sell
389,523
-26,955
-6% -$1.47M 0.15% 124
2016
Q3
$22.5M Sell
416,478
-12,612
-3% -$810K 0.16% 123
2016
Q2
$31.6M Sell
429,090
-2,888
-0.7% -$204K 0.23% 103
2016
Q1
$27.6M Sell
431,978
-22,152
-5% -$1.4M 0.21% 103
2015
Q4
$31.2M Buy
454,130
+213,573
+89% +$14.1M 0.24% 101
2015
Q3
$14.2M Buy
240,557
+805
+0.3% +$51.1K 0.12% 147
2015
Q2
$16M Buy
239,752
+7,430
+3% +$490K 0.12% 148
2015
Q1
$15M Buy
232,322
+418
+0.2% +$26.2K 0.11% 155
2014
Q4
$13.7M Sell
231,904
-6,956
-3% -$392K 0.1% 154
2014
Q3
$12.2M Sell
238,860
-5,986
-2% -$299K 0.1% 169
2014
Q2
$11.9M Sell
244,846
-54,174
-18% -$2.67M 0.1% 171
2014
Q1
$15.4M Buy
+299,020
New +$15.9M 0.13% 141

Other funds holding BMY

CIBC Private Wealth Group's BMY Position: Q4 2025 in Review

CIBC Private Wealth Group reduced its Bristol-Myers Squibb (BMY) stake by 3.9% in Q4 2025, selling an estimated $523K and leaving 268,354 shares worth $14.5M. The position accounts for 0.02% of the portfolio, ranked #311.

CIBC Private Wealth Group first reported a position in BMY in Q1 2014 and has held it in 48 quarters since. The position peaked at $33.1M in Q2 2022. 2,448 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

  • CIBC Private Wealth Group held 268,354 shares of Bristol-Myers Squibb worth $14.5M as of Q4 2025.
  • CIBC Private Wealth Group sold 10,873 Bristol-Myers Squibb shares in Q4 2025, an estimated $523K.
  • Bristol-Myers Squibb made up 0.02% of CIBC Private Wealth Group's portfolio in Q4 2025, its #311 holding.
  • CIBC Private Wealth Group first reported a position in Bristol-Myers Squibb in Q1 2014 and has held it in 48 quarters since.
  • CIBC Private Wealth Group's Bristol-Myers Squibb position peaked at $33.1M in Q2 2022.
  • 2,448 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.